These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36259437)

  • 1. Seroprevalence of SARS-CoV-2 in a Fully Operative Dentistry Academic Center in Madrid (Spain) During the De-escalation Phase of the COVID-19 Pandemic. Are Our Dentists at Greater Risk?
    Cintora P; Rojo R; Martínez A; Ruíz B; Aragoneses JM
    Oral Health Prev Dent; 2022 Oct; 20():349-353. PubMed ID: 36259437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data.
    Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Oliveros-Acebes E; García-Navarro MJ; Khosravi-Shahi P
    Cancer Treat Rev; 2020 Nov; 90():102102. PubMed ID: 32947121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence, infection, and personal protective equipment use among Colombian healthcare workers during the COVID-19 pandemic.
    Beltrán EO; Martignon S; Coronel-Ruiz C; Velandia-Romero ML; Romero-Sanchez C; Avila V; Castellanos JE
    Front Public Health; 2023; 11():1225037. PubMed ID: 37900032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the COVID-19 pandemic progression in Ecuador through seroprevalence analysis of anti-SARS-CoV-2 IgG/IgM antibodies in blood donors.
    Gaviria A; Tamayo-Trujillo R; Paz-Cruz E; Cadena-Ullauri S; Guevara-Ramírez P; Ruiz-Pozo VA; Cevallos F; Aguirre-Tello V; Risueño K; Yánez MP; Cabrera-Andrade A; Zambrano AK
    Front Cell Infect Microbiol; 2024; 14():1373450. PubMed ID: 38975325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
    Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
    BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.
    de Visscher N; Holemans X; Gillain A; Kornreich A; Lagasse R; Piette P; Ventura M; Thys F
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891515
    [No Abstract]   [Full Text] [Related]  

  • 14. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.
    Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A
    Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
    Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D;
    Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a pediatric monographic hospital in Madrid (Spain).
    Escribano Ceruelo E; Espinel Ruíz MA; Ortega López-Peláez M; Fernández Garoz B; Asensio Antón J; Jiménez García R
    Enferm Infecc Microbiol Clin (Engl Ed); 2022; 40(6):326-329. PubMed ID: 35501285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain.
    Varona JF; Madurga R; Peñalver F; Abarca E; Almirall C; Cruz M; Ramos E; Castellano Vázquez JM
    Int J Epidemiol; 2021 May; 50(2):400-409. PubMed ID: 33434269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Seroprevalence in Healthcare Workers of Kaunas Hospitals during the First Wave of the COVID-19 Pandemic.
    Pereckaitė L; Dambrauskienė A; Urbonienė D; Sadauskas S; Petrikonis K; Naudžiūnas A; Vitkauskienė A
    Medicina (Kaunas); 2021 Feb; 57(2):. PubMed ID: 33562085
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).
    Piron M; Jané M; Ciruela P; Basile L; Martínez A; Puig L; Bes M; Sauleda S
    Blood Transfus; 2022 Sep; 20(5):353-361. PubMed ID: 35175189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon.
    Essomba RG; Bayibeki AN; Lissom A; Ateba PT; Seni N; Fouda CAN; Mbitock SBD; Ebonda ND; Afana SD; Akame S; Tembu AA; Ngamaleu MR; Bimai BCB; Kabo O; Nguwoh PS; Ngounouh CT; Meka MCJ; Kengne M; Likeng JN; Kimessoukie EO; Nkoum BA; Assoumou MCO; Fokam J; Yap Boum II; Ambomo MS; Chadou MJP
    Influenza Other Respir Viruses; 2023 Nov; 17(11):e13222. PubMed ID: 37964992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.